Oral cavity cooling (cryotherapy) provided during high-dose melphalan bolus or short-infusion administration contributes to local vasoconstriction, lower blood circulation, lower local cytotoxic drug exposure and significantly reduced oral mucositis (OM) incidence.
. 1, [7] [8] [9] We decided to analyze the impact of reduced OM incidence (reduced oral tissue damage) on acute GVHD, and analyzed 142 prospectively observed patients after Flu/Mel (fludarabine 30 mg/m 2 i.v. once daily for 4 days, melphalan 140 mg/m 2 i.v. one day before transplantation) allo-SCT performed at our institution from January 2005 to December 2010. First 90 patients were not provided with prophylactic oral cryotherapy, as this intervention was implemented into oral cavity care first in January 2009. The cryotherapy with ice lollipops, ice-cold water or crushed ice started 5 min before the melphalan administration, continued during the 15 min of the drug infusion and 15 min afterwards. The patients were instructed to keep the ice or water in their mouth, to gargle it, spit it out or swallow it occasionally.
OM and acute GVHD incidence were compared between the oral cryotherapy (n ¼ 52) and non-cryotherapy group (n ¼ 90) of patients. The oral cryotherapy provision was the only treatment and nursing modality difference between the two groups. The patients were given leuco-depleted and irradiated (25 Gy) erythrocyte and platelet transfusions, filgrastim 5 mg/kg/day was administered from day þ 5 to support engraftment. GVHD prophylaxis consisted of CYA from day À1 and MTX 10 mg/m 2 i.v. on day þ 1, þ 3 and þ 6 with rescue leucovorine. Standard antimicrobial prophylaxis was administered and pre-emptive therapy with ganciclovir was used in CMV infections. OM was assessed using the WHO grading 0 to 4. GVHD was assessed using the NIH-National Institutes of Healthscheme. 10 Overall grading of acute GVHD was assessed by the Glucksberg's system with grades 0 to 4. Basic statistical univariate analyses (Fisher's exact two-tailed test and unpaired t-test) were performed using statistical software (GraphPad Software, La Jolla, CA, USA), and the Pvalues o0.05 were considered as indicating statistically significant differences. In the group of 52 cryotherapy patients, OM developed in 13/52 (25%), OM grade I affected 17% (9/52), II: 2% (1/52), III: 4% (2/52) and IV: 2% (1/52) patients. The complication manifested on median day þ 8 (5-11) posttransplant, persisted for 4 (1-16) days and resolved on day þ 12 (12-21). Acute GVHD developed in 27/52 (52%) patients with the median onset on day þ 20 (13-140) posttransplant and affected skin, gut and livers in 26/27 (96%), 23/27 (85%) and 7/27 (26%) of the GVHD patients. The severity of GVHD (Glucksberg's global grading) was: grade I: 2/27 (7,5%), II: 22/27 (81,5%), III: 3/27 (11%) and IV: 0/27.
As expected, the incidence of OM and severe OM (grade 3-4 WHO) was significantly lower in the oral cryotherapy group: 78 vs 25% (Po0.0001) and 23 vs 2% (P ¼ 0.0094). The incidence of acute GVHD and acute GVHD grade II-IV (Glucksberg's global grading) was not statistically different and tended to be even higher in the oral cryotherapy group: 39 vs 52% (P ¼ 0.1608) and 38 vs 48% (P ¼ 0.289). See Table 1 for more details.
In our previous analysis of 101 FLU/MEL patients, 4 we showed significant dependency of acute GVHD on severity and prolonged duration of OM. Patients with OM persisting on day þ 21 and later, had more acute GVHD (68 vs 32%, P ¼ 0.005), it tended to occur earlier than among those without such prolonged OM, and in half of the patients with OM persisting on day þ 21 and later the activity of acute GVHD was present at the same time. All these findings showed a close relation of the processes having roles in pathogenesis of both the OM and acute GVHD, where early occurring GVHD could keep up and prolong the persistence of originally toxic mucositis, and severe and prolonged OM increased the risk of acute GVHD incidence.
In our present analysis, we were not able to show, that reduced oral tissue damage (OM respectively) leads to reduced acute GVHD incidence. Of course, some other factors capable of modifying acute GVHD could have 
